Regentis Biomaterials Ltd. RGNT
1.33 USD +0.06 (+4.72%)
At closeNov 10, 2026, 7:46 PM EST
1.27 -0.06 -4.51%
After hours · Nov 10, 7:46 PM ET
1.20 Day range 1.34
1.16 52-week range 15.50
- YTD
- -80.27%
- 1 year
- -82.27%
News
benzinga.com Regentis Biomaterials Strikes Distribution Deal With AMI Medical Technologies To Commercialize GelrinC In Israel Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced that it has entered into a
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Glaukos (NYSE:GKOS) shares rose 30.8% to $237.26 during Thursday's regular session. The company's market cap stands at $10.7 billion. The company's, Q3 earnings came out yesterday. Teladoc…- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers SciSparc (NASDAQ:SPRC) shares moved upwards by 39.4% to $1.52 during Monday's pre-market session. Xencor (NASDAQ:XNCR) stock moved upwards by 29.46% to $32.6. The company's market cap stands…
accessnewswire.com Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal Engagement with leading orthopedic surgeons and cartilage repair specialists highlights growing awareness of GelrinC's off-the-shelf regenerative technology GelrinC is CE Mark approved in Europe,…
accessnewswire.com Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City HERZLIYA, IL / ACCESS Newswire / October 9, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular session. The company's market cap stands at $9.0 million. GRAIL (NASDAQ:GRAL) shares moved upwards by 31.47%…
globenewswire.com IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd. AUSTIN, Texas, Sept. 18, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce…
benzinga.com Regentis Biomaterials H1 EPS $(0.44) Up From $(1.17) YoY Regentis Biomaterials (AMEX:RGNT) reported quarterly losses of $(0.44) per share. This is a 62.39 percent increase over losses of $(1.17) per share from the same period last year.
accessnewswire.com Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update Advances GelrinC® U.S. pivotal trial with 43 patients treated; Completion of enrollment expected by approximately year end 2026 Expands European commercialization readiness, including surgeon…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market session. The market value of their outstanding shares is at $1.5 million. CalciMedica (NASDAQ:CALC)…
benzinga.com Regentis Gets Japan Patent Office Notice of Allowance For Organic Solvent‑Free Protein‑Polymer Conjugate Compositions, Covering GelrinC Manufacturing Process And Ready‑to‑Use Liquid Formulation for Articular Cartilage Repair Patent expands intellectual property protection in one of the world's largest cartilage repair marketsGelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need…
accessnewswire.com Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology Patent expands intellectual property protection in one of the world's largest cartilage repair markets GelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need…
benzinga.com Regentis Biomaterials Receives European Regulatory Approval For New GelrinC Manufacturing Process The approval comes as Regentis prepares for the commercial launch of GelrinC® in Europe, enabling the Company to manufacture commercial product using a process that increases production yield by…
accessnewswire.com Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch European Notified Body approves next-generation manufacturing process that increases production 5-fold, lowers manufacturing costs, improves safety and enables scalable commercial production…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular session. The market value of their outstanding shares is at $7.8 million. Shuttle Pharmaceuticals…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Can Fite Biopharma (AMEX:CANF) shares rose 43.8% to $4.27 during Wednesday's regular session. The company's market cap stands at $6.3 million. Regencell Bioscience (NASDAQ:RGC) stock moved…
accessnewswire.com Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement HERZLIYA, IL / ACCESS Newswire / June 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Why Is Regentis Biomaterials Stock Rising On Wednesday? Regentis Biomaterials Ltd. (RGNT) stock rises after withdrawing its Form F-1 registration statement and accelerating European commercialization for GelrinC.
benzinga.com Why La-Z-Boy Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket Shares of La-Z-Boy Inc (NYSE: LZB) rose 19.6% in pre-market trading after reporting better-than-expected results and announcing a $300 million share buyback.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Why High Tide Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket HITI rose sharply in pre-market trading on strong Q2 results and continued to rise after market open. Other gainers include SLBT, TDIC, IMCC, IVDA, NXTS, CRVO, PAVS, ALBT, and PURR. Losers include…
benzinga.com Regentis Biomaterials Slips 9% After Soaring 506% On Monday — Here's Why RGNT Stock Is Trending Regentis stock surged 506% Monday after withdrawing its planned public offering, before slipping in after-hours trading.- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com Crude Oil Tumbles Over 5%; Empire State Manufacturing Index Falls In June US stocks gain on peace agreement with Iran, Nasdaq up 2%, Dow up 1.1%, S&P 500 up 1.54%. Tech shares jump 2.8%, energy stocks fall 3.5%. Empire State manufacturing index drops to 5.7. Industrial…
benzinga.com Regentis Biomaterials Withdraws F-1 Registration Statement And Cancels Planned Public Offering https://www.sec.gov/Archives/edgar/data/1912966/000121390026068601/ea0294796-6k_regentis.htm
benzinga.com Dow Jumps Over 600 Points Following US-Iran Peace Deal US stocks rise on peace agreement with Iran, Dow up 600 points. Tech sector jumps, energy stocks down. Trump announces deal, oil futures decline.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT, MTEN, NCRA, ZTG, EPSM, DBI, APLD. Losers include BYAH, NOTV.- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
accessnewswire.com Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate GelrinC®, positioned as the first off-the-shelf cell-free hydrogel implant for knee cartilage repair, is approved for sale in the European Union Regentis is growing its network of European Centers of…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Sterling Infrastructure Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket Shares of Sterling Infrastructure Inc (NASDAQ: STRL) jumped 22.5% in pre-market trading after reporting better-than-expected Q1 results and raising its FY26 guidance. Other gainers include BLZE,…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Regentis Biomaterials Partners With Humanitas Research Hospital In Italy Over Expanding Clinical Activities In Europe Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced a collaboration with…
accessnewswire.com Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon Collaboration with leading European orthopedic center in Italy supports GelrinC® clinical adoption Renowned cartilage regeneration expert Prof. Elizaveta Kon to help lead Regentis Centers of…- benzinga.com Regentis Biomaterials Develops New Manufacturing Process For GelrinC, Off-The-Shelf Hydrogel Synchronized Erosion And Resorbable Implant For Treatment Of Painful Injuries To Focal Articular Knee Cartilage Breakthrough manufacturing process comes in preparation for upcoming commercial launch in Europe planned for later this yearProprietary process is already patented in several countries and is pending…
accessnewswire.com Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400% Breakthrough manufacturing process comes in preparation for upcoming commercial launch in Europe planned for later this year Proprietary process is already patented in several countries and is…
accessnewswire.com Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update $7.4 million in cash expected to provide runway to complete site expansion process and patient enrollment as part of pivotal Phase III FDA trial for GelrinC Already approved in Europe, GelrinC is…
accessnewswire.com Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer: Brings Strong Track Record of Success in Cartilage Repair Dr. Reske has proven leadership in clinical development and regulatory affairs following key role in FDA approval of cartilage repair product Agili-C leading to CartiHeal's $330 million acquisition…
benzinga.com Regentis Biomaterials Names Ori Gon Chief Financial Officer And Chief Business Officer, As GelrinC Progresses In US Food and Drug Administration Phase III Trial GelrinC, the only restorative product for knee cartilage repair, has CE Mark approval in Europe and is currently at the midpoint of a pivotal FDA Phase III trial in the U.S.Ori Gon brings substantial…
accessnewswire.com Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial GelrinC, the only restorative product for knee cartilage repair, has CE Mark approval in Europe and is currently at the midpoint of a pivotal FDA Phase III trial in the U.S. Ori Gon brings…
accessnewswire.com Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S. New sites expected to further accelerate patient enrollment, which surpassed 50% in Phase III study, as well as support future clinical programs GelrinC is set to transform cartilage repair market…- benzinga.com Regentis Biomaterials GelrinC Demonstrates True Hyaline Cartilage Regeneration Two Years Post-Treatment In Long-Term Clinical Trial Data 2 years after treatment, GelrinC-treated patients demonstrated layered cartilage architecture similar to native hyaline cartilage - widely regarded as the gold standard for durable joint functionThis…